APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
Open Access
- 1 February 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (2), e01715-18
- https://doi.org/10.1128/aac.01715-18
Abstract
Coccidioidomycosis is a systemic fungal infection caused by the inhalation of the arthroconidia of either of two closely related dimorphic fungi, Coccidioides immitis and C. posadasii, that are endemic in the southwestern United States and other areas in the Western Hemisphere. Chronic cavitary pulmonary infections and extrapulmonary sites of infection are very difficult to treat and often require lifelong azole therapy. APX001A is the first in a new class of broad-spectrum antifungal agents that inhibit Gwt1, an enzyme which is required for cell wall localization of glycosylphosphatidylinositol (GPI)-anchored mannoproteins in fungi. APX001A and several analogs were highly active against clinical isolates of Coccidioides, inhibiting hyphal growth at low nanogram/ml concentrations. APX001 is the N-phosphonooxymethyl prodrug of APX001A, currently in clinical trials for the treatment of invasive fungal infections. Mice were treated orally once daily with 26 mg/kg/day of APX001 and the prodrug analog APX2097, 2 h after administration of the pan-cytochrome P450 inhibitor 1-aminobenzotriazole, which was used to enhance drug half-life and exposures to more closely mimic human pharmacokinetics of APX001A. Five days of treatment reduced lung colony counts by nearly 3 logs and prevented dissemination, similar to the efficacy of fluconazole dosed orally at 25 mg/kg twice daily. In a survival experiment, both APX001- and APX2097-treated mice survived significantly longer than control and fluconazole-treated mice. APX001 and other members of this new class of antifungal agents may offer great promise as effective therapies for coccidioidomycosis.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (1R44AI125017-01)
This publication has 36 references indexed in Scilit:
- Gene expression in human fungal pathogen Coccidioides immitis changes as arthroconidia differentiate into spherules and matureBMC Microbiology, 2013
- Dectin-1 Is Required for Resistance to Coccidioidomycosis in MicemBio, 2013
- Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances ImmunogenicityACS Chemical Biology, 2012
- Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular MethodsAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution MethodsAntimicrobial Agents and Chemotherapy, 2011
- Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and FusariosisAntimicrobial Agents and Chemotherapy, 2011
- Amphotericin B and CoccidioidomycosisAnnals of the New York Academy of Sciences, 2007
- Coccidioidomycosis—A Fungal Disease of the AmericasPLoS Medicine, 2005
- Novel Prodrug Approach for Tertiary Amines: Synthesis and Preliminary Evaluation of N-Phosphonooxymethyl ProdrugsJournal of Medicinal Chemistry, 1999
- Coccidioidomycosis: A Reemerging Infectious DiseaseEmerging Infectious Diseases, 1996